Brand-name vs compounded
Hers vs SnagRx: Brand-Name or Compounded? (2026)
Hers costs $1,788 a year against $1,188 for SnagRx. Full 2026 comparison of price, medication class and included support.
Published · Pricing as published in our provider dataset, synced · Editorial scores 9.8 and 7.5 out of 10
We may receive compensation when you click partner links. Rankings are based on research methodology, not sponsorship.
Hers versus SnagRx is a common shortlist, and it is a more interesting one than the two homepages suggest.
Hers dispenses brand-name, FDA-approved finished medication. SnagRx dispenses compounded medication prepared by a pharmacy rather than manufactured under an approved application. Those are different regulatory categories, and the price difference between them is the whole reason both business models exist.
Each program is read on its own published terms first, then against the other on the four things that decide satisfaction: price, predictability, formulary and access to a clinician. Where a provider quotes only after intake, that is recorded as the answer rather than replaced with a guess.
The short answer
- Lowest 12-month cost
- SnagRx — $828 against $1,788 at Hers, on each provider's own best published pricing.
- FDA-approved medication
- Hers — FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen — a finished product the FDA has reviewed, rather than a compounded preparation.
- Tirzepatide access
- SnagRx — Tirzepatide at $149/mo; the other side publishes semaglutide only.
- Widest medication choice
- Hers — FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen.
Hers vs SnagRx at a glance
Scan the pricing rows first, then the medication row. Those two settle most of these decisions between them.
| Hers | SnagRx | |
|---|---|---|
| Advertised price | Wegovy pill from $149/mo, injectable from $199/mo | Semaglutide $99/mo month-to-month, or $69/mo on the 12-month plan |
| Rate after promotions | $149/mo | $99/mo |
| Pricing structure | Published rate per medication | Flat rate at every dose |
| Medication | FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen | Compounded semaglutide and compounded tirzepatide |
| Support model | Provider check-ins included | No coaching program stated |
| Shipping | Home delivery, no insurance required | Free next-day UPS or FedEx in temperature-controlled packaging |
| Price transparency | Published upfront | Published upfront |
| Tirzepatide | Not published | $149/mo |
| Patient reviews | 6,200 | 9,860 |
| eRxDoctor score | 9.8/10 | 7.5/10 |
The real cost: six months and twelve
Both providers lead with a number designed to get you through the intake. What matters is the total at the point most people are still in treatment, so both programs are extended to six and twelve months below.
| Hers | SnagRx | |
|---|---|---|
| First month | $149 | $99 |
| Months 2 onward | $149/mo | $99/mo |
| 6-month total | $894 | $594 |
| 12-month total | $1,788 | $1,188 |
| Best published plan | No multi-month discount published | 12-month semaglutide plan at $69/mo ($828 a year) — $828/yr |
Over a year that is a $960 difference, in SnagRx's favor. Whether it is the right call depends on whether Hers gives you $80 a month of something you will use.
Approved medication or compounded preparation
On Hers's side of the line sits FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen — product manufactured under an approved application, with the batch-to-batch consistency that approval requires.
SnagRx works with compounded semaglutide and compounded tirzepatide. Compounding is what puts $99/mo within reach; it also means no approval application stands behind the specific product you receive.
Neither choice is wrong, but they are different risks. Paying $149/mo buys regulatory certainty. Paying less buys access, on terms where the manufacturing oversight is not the same.
How Hers works
Hers offers FDA-approved Wegovy® (brand-name semaglutide) with a personalized care team and ongoing dose check-ins, no compounded medications. What it is really selling here is brand-name Wegovy at a price that usually buys compounded medication elsewhere.
You start with online intake with clinician review; medication arrives via home delivery, no insurance required. The price behaves as published rate per medication.
Ongoing care is personalized care team with ongoing dose check-ins, and the medication list runs to FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen.
Hers pros
- No insurance required
- FDA-approved brand-name Wegovy®, not a compounded product
- Personalized care team with ongoing dose check-ins
Hers cons
- No compounded/generic alternative offered
- Higher starting price than most compounded competitors
The reservation worth holding, particularly next to SnagRx: there is no compounded tier to fall back on if the brand-name price stops working for you.
A closer look at SnagRx
SnagRx offers compounded semaglutide from $69/month and tirzepatide from $119/month, with the rate locked flat at every dose, named US 503A pharmacies and next-day shipping. Against Hers, that puts it in the position of the cheaper option.
From signup to first shipment: 5-minute intake, clinician review typically within 5 hours and always within 24, then free next-day UPS or FedEx in temperature-controlled packaging. Billing follows a flat rate at every dose structure.
Behind the prescription sits 1:1 nursing staff plus a secure patient portal for refills and dose changes. Available medication: compounded semaglutide and compounded tirzepatide.
SnagRx pros
- Full refund if the prescription is declined, plus a 6-month weight-loss guarantee (terms apply)
- Clinician review typically within 5 hours; next-day temperature-controlled shipping
- States LegitScript certification, which patients can verify independently
- Names its four US 503A partner pharmacies and its clinician network (OpenLoop Health)
SnagRx cons
- No coaching or nutrition programming of any kind
- Heavy urgency marketing, including a countdown timer on the pricing page
- The advertised $69 and $119 rates require the 12-month plan; month-to-month is $99 and $149
The cost of choosing this over Hers: the advertised $69 and $119 rates require the 12-month plan — month-to-month is $99 and $149.
Hers or SnagRx: matching the program to the patient
Choose Hers if:
- you want an FDA-approved finished medication rather than a compounded preparation
- the feature you would actually use: brand-name Wegovy at a price that usually buys compounded medication elsewhere
- the level of clinical contact suits you: personalized care team with ongoing dose check-ins
- you want to start on their timeline: online intake with clinician review
Choose SnagRx if:
- you want the price you sign up at to survive titration
- the monthly rate is the constraint — $99/mo against $149/mo
- you are willing to commit for a term in exchange for a lower effective rate (12-month semaglutide plan at $69/mo ($828 a year))
- you want tirzepatide available without changing provider later
The compromises on both sides
On price. SnagRx is the cheaper program at $99/mo against $149/mo. What SnagRx gives up for that is the advertised $69 and $119 rates require the 12-month plan — month-to-month is $99 and $149; what Hers charges for is brand-name Wegovy at a price that usually buys compounded medication elsewhere.
On access. Hers advertises online intake with clinician review and home delivery, no insurance required; SnagRx advertises 5-minute intake, clinician review typically within 5 hours and always within 24 and free next-day UPS or FedEx in temperature-controlled packaging. Coverage differs too — not published against 48 states — which decides the question before price does if you are in a restricted state.
On predictability. Published rate per medication versus flat rate at every dose. Whichever you pick, get the maintenance-dose price in writing at intake.
On clinical contact. Hers provides personalized care team with ongoing dose check-ins. SnagRx provides 1:1 nursing staff plus a secure patient portal for refills and dose changes. Both are asynchronous-first services and neither replaces a physician who can examine you.
The medication, not the platform
Neither Hers nor SnagRx manufactures the molecule it prescribes, and the clinical evidence behind GLP-1 treatment belongs to the drug rather than to any platform selling access to it.
The NIH position is that weight-management medication works alongside changes in eating and activity, not instead of them, per NIH, NIDDK.
Cardiovascular benefit has been demonstrated for semaglutide in a specific population: adults with overweight or obesity and existing cardiovascular disease but no diabetes, per NEJM, SELECT.
Read alongside the pricing above, that is the case for treating the medication decision as clinical and the provider decision as commercial. They are not the same choice.
Hers vs SnagRx: common questions
Which is cheaper to start, Hers or SnagRx?
SnagRx, at $99 against $149. Note that the cheapest first month and the cheapest year are often different providers here — check the 12-month row of the cost table before deciding on the entry price.
Which has more patient reviews, Hers or SnagRx?
SnagRx, with 9,860 against 6,200. Ratings across this market cluster tightly, so volume is the more useful signal: it indicates how much operational load the platform has already absorbed, not how good the medication is.
Do Hers or SnagRx take insurance?
Both run on a direct-pay basis: you pay the platform and it does not bill your insurer. Neither publishes HSA/FSA acceptance, so budget the full amount as out-of-pocket spending.
How fast can I start with Hers compared with SnagRx?
Hers advertises online intake with clinician review, with home delivery, no insurance required. SnagRx advertises 5-minute intake, clinician review typically within 5 hours and always within 24, with free next-day UPS or FedEx in temperature-controlled packaging. Both are subject to clinician review and to whether your state and health history clear, so treat the advertised timeline as a best case rather than a commitment.
Can I switch from Hers to SnagRx later?
Yes. Neither program locks you in clinically, and both operate month to month unless you have bought a multi-month plan. Practically, switching means a fresh intake, a fresh clinician review and possibly a gap in supply, so time it against your current shipment rather than your renewal date, and check the refund terms on any prepaid plan first.
The verdict
On the numbers, SnagRx wins the year: $828 against $1,788. That is the default answer, and it is the right one for anyone who mainly needs a reliable prescription and a shipment that arrives.
Where Hers justifies itself is brand-name Wegovy at a price that usually buys compounded medication elsewhere. Where it does not is anywhere the extra spend buys features you will never open.
The failure mode here is not picking the wrong platform; it is stopping treatment because the bill moved. Choose the one whose bill you can predict.
Keep comparing
- Hers vs TrimRxBrand-name vs compounded
- Shed vs HersPublished price vs quote-only
- SnagRx vs Mochi HealthLocked price vs escalating price
- SnagRx vs IVIM HealthLocked price vs escalating price
- Directmeds vs Ro.coBrand-name vs compounded
- Enhance MD vs Ro.coBrand-name vs compounded
See every provider in context on the weight loss rankings, or browse the full comparison index.
Disclaimers and methodology
Medical content is informational only and does not replace professional diagnosis, treatment, or emergency care.
Some links are affiliate links and may generate commission at no extra cost to you.
Pricing reflects what each provider published as of the sync date above and changes frequently; confirm the current rate, and the rate at your maintenance dose, before you pay. Six- and twelve-month totals are calculated from those published rates and exclude anything a provider bills separately.
eRxDoctor is an independent publisher. It is not a medical provider, is not affiliated with or endorsed by Hers or SnagRx, and does not sell treatment. Read our ranking methodology.